Becton, Dickinson and Company (NYSE:BDX – Get Free Report) EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president directly owned 14,856 shares of the company’s stock, valued at $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Becton, Dickinson and Company Stock Performance
NYSE:BDX opened at $183.16 on Friday. The company has a 50-day moving average of $157.84 and a 200-day moving average of $161.70. The firm has a market cap of $50.47 billion, a price-to-earnings ratio of 55.17, a price-to-earnings-growth ratio of 12.82 and a beta of 0.19. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the previous year, the firm earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.
Becton, Dickinson and Company Announces Dividend
Wall Street Analyst Weigh In
BDX has been the subject of several recent analyst reports. Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday. Royal Bank Of Canada boosted their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a report on Thursday. Bank of America reduced their price target on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Finally, TD Cowen lifted their price objective on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $185.67.
Read Our Latest Stock Report on BDX
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Auto Owners Insurance Co lifted its position in Becton, Dickinson and Company by 22,225.2% in the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after buying an additional 40,528,680 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Becton, Dickinson and Company by 13.0% during the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock valued at $7,118,282,000 after acquiring an additional 4,223,149 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Becton, Dickinson and Company in the second quarter worth $3,721,533,000. State Street Corp raised its holdings in shares of Becton, Dickinson and Company by 0.8% during the fourth quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier’s stock worth $2,714,871,000 after acquiring an additional 116,737 shares in the last quarter. Finally, First Eagle Investment Management LLC raised its holdings in shares of Becton, Dickinson and Company by 16.5% during the fourth quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock worth $2,260,139,000 after acquiring an additional 1,651,592 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.
About Becton, Dickinson and Company
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Articles
- Five stocks we like better than Becton, Dickinson and Company
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
